Participants 83 123 4
in advanced epithelial ovarian carcinoma
Participants 182 385 8
patients randomised in a previously reported multicentre phase III study of topotecan versus paclitaxel in patients with advanced epithelial ovarian cancer who had failed one prior platinum-based regimen
Participants 408 456 7
Patients with bidimensionally measurable disease
Participants 957 969 8
226 patients
Participants 1822 1859 4
group of patients receiving topotecan
Participants 1863 1888 4
relapse of ovarian cancer
